NB-002 (Suzhou Luosheng Bio-Pharmaceutical)

N/A

Report date: 2023/12/13 15:09:21

Base Information

Drug NameNB-002 (Suzhou Luosheng Bio-Pharmaceutical)

Drug Alias NameNB-002NB-002 (Suzhou Luosheng Bio-Pharmaceutical)NB-002 (逻晟生物)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-Hepatitis A virus cellular receptor 2

TargetsHepatitis A virus cellular receptor 2

Therapy Area/IndicationsSolid tumoursNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesNeoLogics Bioscience Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesNeoLogics Bioscience Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A